{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:53:47Z","timestamp":1769050427357,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This research is not funded"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00277-019-03620-2","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T01:02:30Z","timestamp":1548982950000},"page":"1533-1535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inhibitor eradication in refractory acquired hemophilia with lenalidomide"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-7402","authenticated-orcid":false,"given":"C.","family":"Pfrepper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Poenisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pierer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Metze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Petros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"issue":"7","key":"3620_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","volume":"125","author":"A Tiede","year":"2015","unstructured":"Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kuhne A, Gottstein S, Geisen U, Schenk J, Scholz U, Schilling K, Neumeister P, Miesbach W, Manner D, Greil R, von Auer C, Krause M, Leimkuhler K, Kalus U, Blumtritt JM, Werwitzke S, Budde E, Koch A, Knobl P (2015) Prognostic factors for remission of and survival in acquired hemophilia A (AHA). Results from the GTH-AH 01\/2010 study. Blood 125(7):1091\u20131097. \n                    https:\/\/doi.org\/10.1182\/blood-2014-07-587089","journal-title":"Blood"},{"issue":"1","key":"3620_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","volume":"120","author":"P Collins","year":"2012","unstructured":"Collins P, Baudo F, Knoebl P, Levesque H, Nemes L, Pellegrini F, Marco P, Tengborn L, Huth-Kuhne A, on behalf of the EACH2 registry collaborators (2012) Immunosuppression for acquired hemophilia A. Results from the European Acquired Haemophilia Registry (EACH2). Blood 120(1):47\u201355. \n                    https:\/\/doi.org\/10.1182\/blood-2012-02-409185","journal-title":"Blood"},{"issue":"1","key":"3620_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-0036-1597648","volume":"43","author":"GP Br\u00e1s","year":"2017","unstructured":"Br\u00e1s GP, Pinto RJSM, Carvalho MMMC, Fernandes S, Andrade J, Guimar\u00e3es J (2017) Bortezomib. Potential key role in the treatment of multiple myeloma-related acquired hemophilia a. Semin Thromb Hemost 43(1):109\u2013112. \n                    https:\/\/doi.org\/10.1055\/s-0036-1597648","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"3620_CR4","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/bjh.14185","volume":"178","author":"JD McFadyen","year":"2017","unstructured":"McFadyen JD, Tran H, Kaplan ZS (2017) Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A. Br J Haematol 178(6):986\u2013987. \n                    https:\/\/doi.org\/10.1111\/bjh.14185","journal-title":"Br J Haematol"},{"issue":"9","key":"3620_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2217\/imt.15.66","volume":"7","author":"ST Pellom","year":"2015","unstructured":"Pellom ST, Dudimah DF, Thounaojam MC et al (2015) Modulatory effects of bortezomib on host immune cell functions. Immunotherapy 7(9):1011\u20131022. \n                    https:\/\/doi.org\/10.2217\/imt.15.66","journal-title":"Immunotherapy"},{"issue":"1","key":"3620_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","volume":"1","author":"S Ratnasingam","year":"2016","unstructured":"Ratnasingam S, Walker PA, Tran H, Kaplan ZS, McFadyen JD, Tran H, Teh TC, Fleming S, Catalano JV, Chunilal SD, Johnston A, Opat SS, Shortt J (2016) Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv 1(1):31\u201335. \n                    https:\/\/doi.org\/10.1182\/bloodadvances.2016001412","journal-title":"Blood Adv"},{"issue":"7","key":"3620_CR7","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander T, Sarfert R, Klotsche J, K\u00fchl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74(7):1474\u20131478. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2014-206016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3620_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/art.33333","volume":"64","author":"HT Ichikawa","year":"2012","unstructured":"Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH (2012) Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 64(2):493\u2013503. \n                    https:\/\/doi.org\/10.1002\/art.33333","journal-title":"Arthritis Rheum"},{"issue":"58","key":"3620_CR9","doi-asserted-by":"publisher","first-page":"98200","DOI":"10.18632\/oncotarget.21516","volume":"8","author":"B Neuber","year":"2017","unstructured":"Neuber B, Dai J, Waraich WA, Awwad MHS, Engelhardt M, Schmitt M, Medenhoff S, Witzens-Harig M, Ho AD, Goldschmidt H, Hundemer M (2017) Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells. Oncotarget 8(58):98200\u201398214. \n                    https:\/\/doi.org\/10.18632\/oncotarget.21516","journal-title":"Oncotarget"},{"issue":"34","key":"3620_CR10","doi-asserted-by":"publisher","first-page":"36032","DOI":"10.18632\/oncotarget.5506","volume":"6","author":"L Zhang","year":"2015","unstructured":"Zhang L, Bi E, Hong S, Qian J, Zheng C, Wang M, Yi Q (2015) CD4+ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma. Oncotarget 6(34):36032\u201336040. \n                    https:\/\/doi.org\/10.18632\/oncotarget.5506","journal-title":"Oncotarget"},{"issue":"11","key":"3620_CR11","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00277-016-2775-y","volume":"95","author":"E Balaian","year":"2016","unstructured":"Balaian E, Schuster C, Sch\u00f6nefeldt C, Germing U, Haase D, Tuve S, Ordemann R, Ehninger G, Bornh\u00e4user M, Oelschlaegel U, Mohr B, von Bonin M, Platzbecker U, Wermke M (2016) Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q. Ann Hematol 95(11):1805\u20131810. \n                    https:\/\/doi.org\/10.1007\/s00277-016-2775-y","journal-title":"Ann Hematol"},{"issue":"2","key":"3620_CR12","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1038\/emm.2016.143","volume":"49","author":"B Lopez-Millan","year":"2017","unstructured":"Lopez-Millan B, La Diaz de Guardia R, Roca-Ho H, Garc\u00eda-Herrero CM, Lavoie JR, Rosu-Myles M, Gonzalez-Rey E, O'Valle F, Criado G, Delgado M, Menendez P (2017) Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Exp Mol Med 49(2):e290. \n                    https:\/\/doi.org\/10.1038\/emm.2016.143","journal-title":"Exp Mol Med"},{"issue":"6","key":"3620_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/0961203316676377","volume":"26","author":"EY Wu","year":"2017","unstructured":"Wu EY, Schanberg LE, Wershba EC, Rabinovich CE (2017) Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus. Lupus 26(6):646\u2013649. \n                    https:\/\/doi.org\/10.1177\/0961203316676377","journal-title":"Lupus"},{"issue":"9","key":"3620_CR14","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.3109\/10428194.2014.914203","volume":"55","author":"V Montefusco","year":"2014","unstructured":"Montefusco V, Galli M, Spina F, Stefanoni P, Mussetti A, Perrone G, de Philippis C, Dalto S, Maura F, Bonini C, Rezzonico F, Pennisi M, Roncari L, Soldarini M, Dodero A, Farina L, Cocito F, Caprioli C, Corradini P (2014) Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma. Selective occurrence after lenalidomide. Leuk Lymphoma 55(9):2032\u20132037. \n                    https:\/\/doi.org\/10.3109\/10428194.2014.914203","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3620_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/10428194.2016.1204657","volume":"58","author":"JM Loree","year":"2017","unstructured":"Loree JM, Cai E, Sheffield BS, Dutz JP, Villa D, Shepherd LE, Connors JM, Sehn LH, Savage KJ (2017) Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. Leuk Lymphoma 58(3):711\u2013714. \n                    https:\/\/doi.org\/10.1080\/10428194.2016.1204657","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"3620_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.11406\/rinketsu.56.496","volume":"56","author":"M Saburi","year":"2015","unstructured":"Saburi M, Ohtsuka E, Itani K, Nagamatsu K, Ikebe T, Miyazaki Y, Ogata M, Saburi Y (2015) Development of acquired hemophilia a during treatment of multiple myeloma with lenalidomide. Rinsho Ketsueki 56(5):496\u2013500. \n                    https:\/\/doi.org\/10.11406\/rinketsu.56.496","journal-title":"Rinsho Ketsueki"},{"issue":"11","key":"3620_CR17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","volume":"63","author":"WMT Braga","year":"2014","unstructured":"Braga WMT, da Silva BR, de Carvalho AC et al (2014) FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunol Immunother 63(11):1189\u20131197. \n                    https:\/\/doi.org\/10.1007\/s00262-014-1589-9","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"3620_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1365-2141.2008.07530.x","volume":"144","author":"S Feyler","year":"2009","unstructured":"Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft AJ, Owen RG, Selby PJ, Cook G (2009) CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(\u2212)CD8(\u2212)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 144(5):686\u2013695. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07530.x","journal-title":"Br J Haematol"},{"issue":"11","key":"3620_CR19","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.4049\/jimmunol.168.11.5893","volume":"168","author":"M Saurwein-Teissl","year":"2002","unstructured":"Saurwein-Teissl M, Lung TL, Marx F, Gschosser C, Asch E, Blasko I, Parson W, Bock G, Schonitzer D, Trannoy E, Grubeck-Loebenstein B (2002) Lack of antibody production following immunization in old age. Association with CD8+CD28- T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 168(11):5893\u20135899. \n                    https:\/\/doi.org\/10.4049\/jimmunol.168.11.5893","journal-title":"J Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03620-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03620-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03620-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T19:09:40Z","timestamp":1580497780000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03620-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["3620"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03620-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]},"assertion":[{"value":"12 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}